Skip to main content
Clinical Trials/CTRI/2017/03/008011
CTRI/2017/03/008011
Completed
未知

sage of Dapagliflozin - a Sodium Glucose Co-transporter inhibitor, in the management of Type-2 Diabetes Mellitus: A Real world evidence study in Indian patients - FOREFRONT

AstraZeneca Pharma India Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: null- Type 2 Diabetes
Sponsor
AstraZeneca Pharma India Ltd
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients who provide written informed consent.
  • 2\. Patients with previously diagnosed Type\-2 diabetes mellitus
  • 3\. Patients with inadequately controlled diabetes (HbA1c \>7%) with existing anti\-diabetic medications, prior to initiation of dapagliflozin treatment.
  • 4\. Patients who are taking dapagliflozin within last 3 months.
  • 5\.Patients who are having past medical records for demographic information, weight, blood pressure and HbA1c value at the time of dapagliflozin prescribed

Exclusion Criteria

  • 1\.Patients with Type\-1 diabetes mellitus
  • 2\. Patients with any medical condition which in the opinion of the investigator would interfere with safe completion of the study
  • 3\. Pregnant or lactating women

Outcomes

Primary Outcomes

Not specified

Similar Trials